Advertisement

Topics

Cara's chronic pain drug data disappoints, shares plunge

13:29 EDT 29 Jun 2017 | Reuters

(Reuters) - Cara Therapeutics Inc reported disappointing data from a key study testing its chronic pain treatment in patients with osteoarthritis, sending the drug developer's shares down about 32 percent after the bell on Thursday.

Original Article: Cara's chronic pain drug data disappoints, shares plunge

NEXT ARTICLE

More From BioPortfolio on "Cara's chronic pain drug data disappoints, shares plunge"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pain Disorder
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...